Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 21Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 3Paraganglioma 3Prostatic Neoplasms 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Adenoma, Islet Cell 2Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Disease Progression 1Digestive System Neuroendocrine Tumor G1 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

Gemcitabine 115130-nm albumin-bound paclitaxel 66Albumin-Bound Paclitaxel 44Fluorouracil 37Magnetic Resonance Spectroscopy 35Irinotecan 35pembrolizumab 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 23Cyclophosphamide 21Nivolumab 18fludarabine 16Radiosurgery 16Cisplatin 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10Carboplatin 10Blood Specimen Collection 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × lutetium Lu 177 dotatate × 1 year × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡